GDR targets22 Jul 2020 09:57
I was just reading through the RNS from the 10th July and looking at the huge target GDR have laid out for themselves.
GDR admit themselves they are very confident they can achieve this goal.
PI's need to stop panicking and hold onto their shares, the SP could easily double or triple from here if they do that
Read the paragraph below from the rns and digest the positive news and information
The Company's main commercial efforts are focussed on India, Africa and the United States:
- Indian approval was applied for in mid-June and the process is ongoing. The Company remains very confident that rapid commercial roll out could be achieved in India through both existing distribution partners and DIVOC Health, a new COVID focussed partner in India.
- The Company has signed a number of distributors across Africa and is in the process of registering the product locally. The CoV-2 Test was submitted for WHO approval in early June, although this is not a primary focus for market entry as many African countries have their own approval processes.
- In the United States, Emergency Use Authorisation (EUA) has been applied for and remains under consideration by the FDA. The Company has been in discussion with several interested partners to access the US market, but all discussions have been subject to receipt of EUA approval.
The Company is also working to ensure that CE marking claims for the Genedrive(R) 96 SARS-CoV-2 test can be expanded to include a broader range of laboratory systems, and therefore increase the potential customer base for this test. The Genedrive 96 SARS-CoV-2 test is a high volume laboratory assay compatible with multiple third party platforms. It was initially CE marked with data generated from the Roche Lightcycler 480 II, and the Company is now validating the data for the ABI 7500 FAST and BioRad CFX96 systems to expand its claims.
In addition, the Company has announced separately the launch of its new CE marked Genedrive(R) 96 Exporter, a new IVD software module for automated results interpretation of the Genedrive(R) 96 SARS-CoV-2 Kit. Genedrive(R) 96 Exporter offers a significant improvement to the native software found on third party PCR platforms.
Sign In
Follow the stocks
